Cipla reported a 61.8 per cent rise in its net profit at Rs.500.01 crore for the quarter ended September, 2012, up from Rs.308.97 crore in the corresponding period in the previous year. The profit before taxation rose by 68 per cent to Rs.661.77 crore from Rs.393.92 crore.
Gross revenue grew by 23.6 per cent to Rs.2,220 crore from Rs. 1,796 crore in the period under reference.
Domestic revenues grew by 13.5 per cent to Rs.961.67 crore from Rs.847.03 crore. The growth in domestic revenues was largely on account of growth in anti-asthma, antibiotics and cardio-vascular therapy segments, a release said. On the international business front, the company said export of formulations grew by 38.2 per cent to Rs.1,038.93 crore from Rs..751.58 crore. Exports of APIs grew by 9 per cent to Rs.173.77 crore from Rs.159.48 crore. Total exports grew by 33 per cent to Rs.1,212.70 crore from Rs.911.06 crore.
